Research Topics
Species | Eveline TrachselSummaryAffiliation: Swiss Federal Institute of Technology Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivoEveline Trachsel
Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
J Invest Dermatol 127:881-6. 2007....- Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritisEveline Trachsel
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Wolfgang Paulistrasse 10, CH 8093 Zurich, Switzerland
Arthritis Res Ther 9:R9. 2007.... - Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapyJessica Mårlind
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland
Clin Cancer Res 14:6515-24. 2008..There is an interest in the discovery of biopharmaceuticals, which are well tolerated and which potentiate the action of anthracyclines and taxanes in breast cancer therapy... - Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritisKathrin Schwager
Philochem AG, c o ETH Zurich, Institute of Pharmaceutical Sciences, Wolfgang Pauli Strasse 10 HCI E520, CH 8093 Zurich, Switzerland
Arthritis Res Ther 11:R142. 2009..Furthermore we have evaluated the therapeutic potential of the most promising antibody, F8, fused to the anti-inflammatory cytokine interleukin (IL) 10... - Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2Christoph Schliemann
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland
Blood 113:2275-83. 2009.... - A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivoAlessandra Villa
Philochem AG, c o ETH Zurich, Wolfgang Pauli Strasse 10, CH 8093 Zurich, Switzerland
Int J Cancer 122:2405-13. 2008.... - Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12Roberto Sommavilla
Philochem AG, c o ETH Zurich, Institute of Pharmaceutical Sciences, Wolfgang Pauli Strasse 10, HCI E520, CH 8093 Zurich, Switzerland
Protein Eng Des Sel 23:653-61. 2010..The positive outcome of this feasibility study leads now to GMP production of F8-IL12, which will soon enter clinical trials... - In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomographyViviane Mumprecht
Institute of Pharmaceutical Sciences and Philochem AG, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland
Cancer Res 70:8842-51. 2010..Immuno-PET with lymphatic-specific antibodies may open up new avenues for the early detection of metastasis, and the images obtained might be used as biomarkers for the progression of diseases associated with lymphangiogenesis... - A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cellsKathrin Zuberbühler
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich, Switzerland
Protein Eng Des Sel 22:169-74. 2009..We expect that these techniques should find broad applicability for both academic and industrial antibody engineering research... - The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse modelKathrin Schwager
Philochem AG, c o ETH Zurich, Institute of Pharmaceutical Sciences, Wolfgang Pauli Str 10 HCI E520, CH 8093 Zurich, Switzerland
Hum Reprod 26:2344-52. 2011..This study investigates the use of derivatives of the human antibody F8, specific to the alternatively spliced extra-domain A of fibronectin (Fn), for the imaging and treatment of endometriosis... - Ligand-based vascular targeting of diseaseJascha N Rybak
ETH Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland
ChemMedChem 2:22-40. 2007.... - An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting propertiesVerena Gafner
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, , Switzerland
Int J Cancer 119:2205-12. 2006.... - The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasisManuela Kaspar
Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland
Cancer Res 67:4940-8. 2007.... - Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosisEveline Trachsel
Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich, Wolfgang-Pauli-Str.10, , HCI G396, , Switzerland
Adv Drug Deliv Rev 58:735-54. 2006..This article reviews some of the most significant advances in these areas, and outlines future challenges and opportunities... - A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanomaThomas K Eigentler
Department of Dermatology, University Medical Center, Tubingen, Germany
Clin Cancer Res 17:7732-42. 2011..5 million international units (Mio IU) IL2 equivalents. In this study, safety and clinical activity of L19-IL2 in combination with dacarbazine were assessed in patients with metastatic melanoma... - Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19)Nicolas Spaeth
PET Center, Division of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
Nucl Med Biol 33:661-6. 2006..However, larger trials with preferentially higher doses are needed to confirm this finding and, potentially, to further increase the efficacy of this treatment...